help button home button The Oncologist http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 12, No. 7, 756-765, July 2007; doi:10.1634/theoncologist.12-7-756
© 2007 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 Lapatinib-Associated Toxicity and Practical Management Recommendations
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moy, B.
Right arrow Articles by Goss, P. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moy, B.
Right arrow Articles by Goss, P. E.

Breast Cancer

Lapatinib-Associated Toxicity and Practical Management Recommendations

Beverly Moy, Paul E. Goss

Massachusetts General Hospital Cancer Center, Gillette Center for Women's Cancers, Boston, Massachusetts, USA

Key Words. Lapatinib • Dual tyrosine kinase inhibitor • Breast cancer • EGFR • ErbB-1 • ErbB-2 HER-2 • Toxicity

Correspondence: Correspondence: Beverly Moy, M.D., M.P.H., Massachusetts General Hospital Cancer Center, Gillette Center for Women's Cancers, 55 Fruit Street, Lawrence House, LRH 304, Boston, Massachusetts 02114, USA. Telephone: 617-726-4920; Fax: 617-643-0589; e-mail: bmoy{at}partners.org

Lapatinib is an oral receptor tyrosine kinase inhibitor, inhibiting both the ErbB-1 and ErbB-2 receptors. Lapatinib has been shown to have activity in ErbB-2–overexpressing breast cancer in several phase II and III clinical trials. Specifically, lapatinib is effective in patients with metastatic breast cancer, with inflammatory breast cancer, and possibly, with brain metastases. An ongoing clinical trial and another anticipated clinical trial will investigate lapatinib as adjuvant treatment in early-stage disease. Lapatinib has specific toxicities, the most common being diarrhea and rash. Cardiac toxicity is rarely seen with lapatinib. This paper reviews lapatinib-associated toxicities and provides practical management recommendations based on available data.

Disclosure of potential conflicts of interest is found at the end of this article.




This article has been cited by other articles:


Home page
 Am Soc Clin Oncol Ed BookHome page
A. Saad, R. Beto, J. Abraham, and S. C. Remick
Cardiovascular Safety and Toxicity Profile of New Molecularly Targeted Anticancer Agents
ASCO Educational Book, January 1, 2008; 2008(1): 428 - 434.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS
http://theoncologist.alphamedpress.org/misc/eLetters.shtml

Copyright © 2007 by AlphaMed Press.